A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-22 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Depending on the concentration of the sample, the magnetic field of the spectrometer, and the type of experiment, a single multidimensional nuclear magnetic resonance experiment on a protein sample may take hours or even several days to obtain suitable signal-to-noise ratio through signal averaging, and to allow for sufficient evolution of magnetization transfer through the various dimensions of the experiment. Other things being equal, higher-dimensional experiments will take longer than lower-dimensional experiments. Typically, the first experiment to be measured with an isotope-labelled protein is a 2D heteronuclear single quantum correlation (HSQC) spectrum, where "heteronuclear" refers to nuclei other than 1H. In theory, the heteronuclear single quantum correlation has one peak for each H bound to a heteronucleus. Thus, in the 15N-HSQC, with a 15N labelled protein, one signal is expected for each nitrogen atom in the back bone, with the exception of proline, which has no amide-hydrogen due to the cyclic nature of its backbone. Additional 15N-HSQC signals are contributed by each residue with a nitrogen-hydrogen bond in its side chain (W, N, Q, R, H, K). The 15N-HSQC is often referred to as the fingerprint of a protein because each protein has a unique pattern of signal positions. Analysis of the 15N-HSQC allows researchers to evaluate whether the expected number of peaks is present and thus to identify possible problems due to multiple conformations or sample heterogeneity.
Flashing Flashing LEDs are used as attention seeking indicators without requiring external electronics. Flashing LEDs resemble standard LEDs but they contain an integrated voltage regulator and a multivibrator circuit that causes the LED to flash with a typical period of one second. In diffused lens LEDs, this circuit is visible as a small black dot. Most flashing LEDs emit light of one color, but more sophisticated devices can flash between multiple colors and even fade through a color sequence using RGB color mixing. Flashing SMD LEDs in the 0805 and other size formats have been available since early 2019. Flickering Simple electronic circuits integrated into the LED package have been around since at least 2011 which produce a random LED intensity pattern reminiscent of a flickering candle. Reverse engineering in 2024 has suggested that some flickering LEDs with automatic sleep and wake modes might be using an integrated 8-bit microcontroller for such functionally. Sometimes a flickering effect might happen due to an electric malfunction. Bi-color Bi-color LEDs contain two different LED emitters in one case. There are two types of these. One type consists of two dies connected to the same two leads antiparallel to each other. Current flow in one direction emits one color, and current in the opposite direction emits the other color. The other type consists of two dies with separate leads for both dies and another lead for common anode or cathode so that they can be controlled independently. The most common bi-color combination is red/traditional green.
Brian Clarke, Artist. For services to Art. Ronald Dennis, , Chair, Podium Analytics and Patron, Tommy's Campaign. For services to Industry and to Charity. Gregory Doran, lately Artistic Director, Royal Shakespeare Company. For services to the Arts. Athelstan Joseph Michael Eavis, , Founder and Leader, Glastonbury Festival. For services to Music and to Charity. Professor William John Edmunds, , Professor, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine. For services to Epidemiology. John Patrick Griffin, Founder, Addison Lee. For services to Business and to Charity. Stephen Alan Michael Hester, Chair, Easyjet and Chair, Nordea. For services to Business and to the Economy. David Charles Holmes, , Chief Executive Officer, Family Action. For services to Children and Families. Professor Amritpal Singh Hungin, , Emeritus Professor of General Practice, Newcastle University. For services to Medicine. Professor John Peter Iredale, , lately Interim Executive Chair, Medical Research Council. For services to Medical Research. The Right Honourable Sajid Javid, , Member of Parliament for Bromsgrove. For Political and Public Service. Timothy Randall Martin, Founder and Chair, Wetherspoons. For services to Hospitality and to Culture. Professor Alexander McCall Smith, , Author and Academic. For services to Literature, to Academia and to Charity Professor Neil James McCready Mortensen, lately President, Royal College of Surgeons of England. For services to Surgery. Gerald Maurice Ronson, , For services to Philanthropy and to the Jewish Community.
Their rough endoplasmic reticulum and Golgi apparatus were still not well developed, indicating that despite the change in shape, the fibroblasts still remained mostly in a resting phase. Few newly released materials were seen adjacent to the fibroblasts. The ground substance content in the infant Reinke's space seemed to decrease over time, as the fibrous component content increased, thus slowly changing the vocal fold structure.
Sources: en.wikipedia.org
A "stop" traffic sign with three 3D military drones painted on by Banksy is unveiled. The artwork has an anti-war theme believed to be relating to the Gaza war. However, it is stolen one hour after its unveiling in Peckham, London. 23 December The Metropolitan Police launches an investigation after a street sign in Peckham, London featuring the work of Banksy is stolen. A man is arrested on suspicion of theft and criminal damage during the first day of investigation. An increase in environmental activists being referred to the Prevent terrorism programme is reported, following the recent rise in disruptive climate protests. 24 December A second man is arrested on suspicion of theft and criminal damage after a road sign featuring work by street artist Banksy was stolen. Home Secretary James Cleverly apologises for a joke about his wife in which he said, "a little bit of Rohypnol in her drink every night" is "not really illegal", just hours after the Home Office announced plans to crack down on spiking. Two teenagers die and three others are injured in a three-car crash in Cramlington, Northumberland. The warmest Christmas Eve since 1997 is recorded, with temperatures of up to 15.3 °C (59.5 °F). British businessman Sir Jim Ratcliffe agrees a deal worth an estimated £1.3bn to buy a 25% share in Manchester United. The Ministry of Defence confirms that HMS Trent will take part in joint military exercises in Guyana in early 2024 as Venezuela renews its claims in the Guyana–Venezuela territorial dispute.
Niemann-Pick disease type C1 protein, which participates in the intracellular movement of cholesterol Patched, the receptor for Hedgehog, a protein that contains covalently bound cholesterol Oxysterols regulate cholesterol homeostasis through liver X receptor (LXR) and sterol regulatory element-binding protein (SREBP) mediated signaling pathway. This protein binds to the sterol-sensing domains of SREBP cleavage-activating protein (SCAP) and HMG CoA reductase, and is essential for the sterol-mediated trafficking of the two proteins. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
By the early 1970s, widespread civil unrest had spurred the re-emergence of anarchy as a topic of discussion and study. The viability of anarchy increasingly became a subject of research, including by those that disregarded it as undesirable. Discussions of the viability of anarchy gained traction in academic circles following the publication of American political philosopher Robert Nozick's 1974 work Anarchy, State, and Utopia. Nozick issued a challenge to mainstream political philosophy, which had become preoccupied with the question of how a state should be organised; he questioned how the existence of the state can be justified and whether anarchy was a viable alternative. Nozick suggested that anarchism be examined by political philosophy, but himself would end up advocating for a minimal state that upheld human rights, instead of complete anarchy. Public choice economists of the time, such as James M. Buchanan and Gordon Tullock, also explored anarchy's viability as a means to maintain social order, but came to characterise it in terms of lawlessness and violent social disorder. In his 1976 work Anarchy and Co-operation, American political scientist Michael Taylor argued that social order exists in counter-position to the state; and in his 1982 Community, Anarchy, and Liberty, he posited that anarchy could only exist in a stable form by maintaining social equality.
Sources: en.wikipedia.org
This article incorporates text from a publication now in the public domain: Chisholm, Hugh, ed. (1911). "Mecklenburg". Encyclopædia Britannica. Vol. 17 (11th ed.). Cambridge University Press. pp. 1018–20.
On March 22, 2023, Valve announced Counter-Strike 2, which utilizes the Source 2 game engine. It was originally announced as a free upgrade to Global Offensive with a summer 2023 release date. On September 1, 2023, it was released as a limited beta, and the game replaced Global Offensive on September 27.
== Medical uses == Vildagliptin is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes as monotherapy in people in whom metformin is inappropriate due to contraindications or intolerance; and in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycemic control.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.